The clone ranger?

Molecular Therapy

Volumn 16, Issue 9, 2008, Pages 1520-1521

  Heslop, Helen E ^a   Brenner, Malcolm K ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE CLONE; MELANOMA; NONHUMAN; NOTE; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 50549087017     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.154     Document Type: Note

References (15)

1. + T cells against NY-ESO-1. N Engl J Med 358: 2698-2703.
2. Weiner, LM (2008). Cancer immunotherapy - the endgame begins. N Engl J Med 358: 2664-2665.
3. Fred Hutchinson Cancer Research Center. Patient's own infection-fighting T cells put late-stage melanoma into long-term remission - without chemotherapy or radiation (18 June 2008).
4. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99: 16168-16173.
5. Pulendran, B and Ahmed, R (2006). Translating innate immunity into immunological memory: Implications for vaccine development. Cell 124: 849-863.
6. Rooney, CM, Smith, CA, Ng, CY, Loftin, SK, Sixbey, JW, Gan, Y et al. (1998). Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recepients. Blood 92: 1549-1555.
7. Bollard, CM, Gottschalk, S, Leen, AM, Weiss, H, Straathof, KC, Carrum, G et al. (2007). Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110: 2838-2845.
8. Straathof, KC, Bollard, CM, Popat, U, Huls, MH, Lopez, T, Morriss, MC et al. (2005). Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105: 1898-1904.
9. Gottschalk, S, Ng, CY, Perez, M, Smith, CA, Sample, C, Brenner, MK et al. (2001). An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive ta virus-specific T cell therapy. Blood 97: 835-843.
10. Till, BG, Jensen, MC, Wang, J, Chen, EY, Wood, BL, Greisman, HA et al. (2008). Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood, e-pub ahead of print 28 May 2008.
11. Dudley, ME, Wunderlich, JR, Robbins, PF, Yang, JC, Hwu, P, Schwartzentruber, DJ et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
12. Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
13. Rossig, C, Bollard, CM, Nuchtem, JG, Rooney, CM, and Brenner MK (2002). Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: Potential for improved immunotherapy. Blood 99: 2009-2016.
14. Rabinovich, GA, Gabrilovich, D, Sotomayor, EM. (2007). Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296.
15. Churchill, WS. Speech delivered at Lord Mayor's Luncheon, Mansion House following the victory at El Alamein, North Africa, London, 10 November 1942.